Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
1. Monopar's ALXN1840 announced for presentation at ANA Annual Meeting. 2. The abstract highlights long-term benefits for Wilson disease patients. 3. ALXN1840 received Abstract of Distinction from ANA. 4. Patient presentations reflect potential market interests in treatments. 5. Monopar focuses on innovative solutions for unmet medical needs.